Studying the origins of childhood acute myeloid leukaemia to identify targets for kinder and more effective treatments
Learning more about leukaemia cells in order to design targeted treatments that can increase survivorship and quality of life.
Detecting lingering brain cancer cells before a tumour grows back
Ependymoma comes back after treatment around half of the time, because some cancer cells are still alive. If doctors could identify these cells and diagnose relapsed ependymoma sooner, children could start treatment earlier.
What are the origins of liver cancer in children and why does treatment sometimes fail?
Understanding how hepatocellular carcinoma develops and what role the immune system plays.
Understanding CaMK1D in diffuse large B cell lymphoma in children
Understanding how a protein affects the growth and development of lymphoma cells in order to build the foundations for safer and more effective treatments.
Why does neurodegeneration occur in Langerhans cell histiocytosis?
Discovering what causes nerve cells to stop working and die years after a Langerhans cell histiocytosis diagnosis.
Exploring new targeted therapy options for acute myeloid leukaemia in babies
Looking for repurposed treatments that can fight leukaemia cells in very young children.
How does MYCN change the way genetic information is read?
Understanding how the MYCN protein changes the amounts of other proteins in the cell by changing the way DNA is processed and translated.
What happens in cells to make neuroblastoma develop and how can we stop this?
Looking at what extra pieces of chromosomes do in neuroblastoma and how these work with the MYCN protein to convert healthy cells into cancer cells.
A new immunotherapy treatment for paediatric high-grade glioma
Creating a new immunotherapy that will attacks collagen in cancer cells, and testing whether it is effective in model systems to make it the best it can be.